Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.
Date
2021-07
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Abstract
Abstract
Early, accurate diagnosis of Alzheimer disease (AD) is essential but remains challenging. Neuropathological hallmarks of AD are β-amyloid neuritic plaques and tau protein neurofibrillary tangles. 18F-Florbetapir is one of several available PET tracers for imaging cortical fibrillary β-amyloid plaques. 18F-Flortaucipir PET was recently approved for evaluating the distribution and density of aggregated neurofibrillary tangles. We present cases of mild cognitive impairment or suspected AD to depict the nuances of flortaucipir distribution and scan interpretation as well as how combined information from amyloid and tau PET may help with differential diagnosis and prognosis.Type
Department
Description
Provenance
Citation
Permalink
Published Version (Please cite this version)
Publication Info
James, Olga G, Alexandra R Linares, Caroline Hellegers, P Murali Doraiswamy and Terence Z Wong (2021). Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. Clinical nuclear medicine, 46(7). pp. 605–608. 10.1097/rlu.0000000000003493 Retrieved from https://hdl.handle.net/10161/24156.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Olga Gennadyevna James
P. Murali Doraiswamy
Murali Doraiswamy MBBS FRCP is Professor of Psychiatry and Professor in Medicine at Duke University School of Medicine where he is a highly cited physician scientist at the Duke Institute for Brain Sciences. He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center. He directs a clinical trials unit that has been involved in the development of many modern diagnostic tests, apps, algorithms, and therapeutics in wide use today. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and co-chaired the innovation advisory council for one of the world’s largest social impact funds dedicated to promoting innovative solutions to reverse age related disorders. He has lectured at leading global forums to advance the forefront of aging and neuroscience research. Moreover as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain. He is the co-author of a popular book The Alzheiemr's Action Plan. Prof. Doraiswamy also serves on the board of several global charities.
Terence Z. Wong
- Anatomic/functional oncologic Imaging: SPECT/CT, PET/CT, novel PET radiotracers
2. Radiotheranostics, Radionuclide therapy of cancer, Radiation Therapy Planning
3. Imaging biomarkers for guiding treatment strategies
4. Multicenter clinical trial development (NCI National Clinical Trials Network)
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.